NEW YORK ─ Lumea and Verily on Wednesday announced a strategic partnership to develop digital pathology products to diagnose, prognose, and guide prostate cancer therapy selection with improved objectivity and efficiency.
Under the agreement, the firms will combine Verily’s artificial intelligence algorithms with Lehi, Utah-based Lumea’s end-to-end digital pathology platform.
Financial and other terms of the agreement were not disclosed.
The firms noted that Verily has developed AI systems for digital pathology to reduce variability and maximize insights from biopsy tissue samples by providing advanced computation for researchers and clinicians. Verily and Lumea said they aim to use Lumea’s digital pathology platform and database of pathology cases to enable Verily to validate its Gleason algorithms for prostate cancer developed in partnership with Google Health.
Additionally, they intend to integrate Verily’s algorithms into Lumea’s digital pathology platform to assist pathologists in identifying and grading prostate cancer within their digital workflows.
South San Francisco, California-based Verily is a sister company to Google, and both firms are owned by parent company Alphabet.